BioAtla’s (BCAB) “Market Outperform” Rating Reiterated at JMP Securities

BioAtla (NASDAQ:BCAB)‘s stock had its “market outperform” rating reissued by investment analysts at JMP Securities in a research report issued on Thursday, Benzinga reports. They currently have a $12.00 target price on the stock. JMP Securities’ target price points to a potential upside of 256.08% from the company’s current price.

Separately, HC Wainwright decreased their price target on BioAtla from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, BioAtla presently has an average rating of “Buy” and a consensus target price of $14.20.

BioAtla Stock Down 2.6 %

Shares of BioAtla stock traded down $0.09 during trading on Thursday, reaching $3.37. The company’s stock had a trading volume of 289,769 shares, compared to its average volume of 443,898. BioAtla has a 12-month low of $1.24 and a 12-month high of $4.07. The company has a market capitalization of $161.56 million, a P/E ratio of -1.32 and a beta of 1.02. The business has a 50 day moving average price of $2.47 and a 200-day moving average price of $2.08.

Hedge Funds Weigh In On BioAtla

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC acquired a new stake in BioAtla during the second quarter worth about $27,000. Panagora Asset Management Inc. acquired a new stake in shares of BioAtla in the third quarter valued at about $90,000. Sectoral Asset Management Inc. grew its stake in shares of BioAtla by 26.9% in the third quarter. Sectoral Asset Management Inc. now owns 706,062 shares of the company’s stock valued at $1,200,000 after buying an additional 149,544 shares in the last quarter. SC&H Financial Advisors Inc. grew its stake in shares of BioAtla by 232.4% in the third quarter. SC&H Financial Advisors Inc. now owns 71,125 shares of the company’s stock valued at $121,000 after buying an additional 49,725 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its stake in shares of BioAtla by 26.4% in the third quarter. Vontobel Holding Ltd. now owns 715,195 shares of the company’s stock valued at $1,216,000 after buying an additional 149,544 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.